Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
10.510USD
+0.160+1.55%
Market hours 11/09, 10:36（ET）
298.69MMarket Cap
LossP/E TTM
Today
+1.55%
5 Days
-4.71%
1 Month
-18.34%
6 Months
+13.99%
Year to Date
+71.45%
1 Year
+20.53%
Key Figures
10.465Open
10.800High
69.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.24%Turnover Ratio
10.350Prev. Close
9.705Low
705.05KTurnover
LossP/E Static
1.74P/B
0.00%Div Yield TTM
-27.26%ROA
17.96052wk High
0.60Volume Ratio
-80.94MNet Profit
28.42MShares
-2.8315EPS TTM
2.37Beta
-37.01%ROE
5.50052wk Low
10.58%Amplitude
100.00%Gross Margin
298.69MMarket Cap
9.41Reward/Risk
5.16%Risk Rate
Arcturus Therapeutics Holdings Inc's Score
0.04vs previous score
Forecast8.31
Financial Health6.36
Technical5.36
Valuation Dimensions7.16
Institutional Confidence7.00
Risk Assessment2.94
Media Coverage
Coverage Level
Very Low
Very High
Negative-
Analyst Rating
Arcturus Therapeutics Holdings Inc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Neutral
Arcturus Therapeutics Holdings Inc Latest Earnings Call Transcripts
Arcturus Therapeutics (ARCT) Q3 2026 Earnings Call: Key Clinical Milestones
Arcturus Therapeutics Q3 2026 earnings call: $18.3 million revenue, a narrower quarterly loss, and 2027 milestones for ARCT-032, ARCT-2601 and LUNAR 2.0.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.26/-0.68
Revenue / Forecast
18.30M/8.00M
Arcturus Therapeutics Holdings Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolARCT
Number of employees174
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Federated Hermes Global Investment Management Corp. | 11.62% |
| ARK Investment Management LLC | 9.74% |
| Amova Asset Management Co., Ltd. | 8.05% |
| BlackRock Institutional Trust Company, N.A. | 7.46% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor/Hedge Fund | 34.57% |
| Investment Advisor | 33.08% |
| Individual Investor | 7.99% |
| Hedge Fund | 7.96% |
Related Instruments
+3.39%
+0.79%
-0.14%
+0.41%
-0.09%
+1.22%
-0.08%
+1.17%
+1.24%
-1.00%
-0.14%
-0.14%
-0.10%
+1.75%
+6.62%
+1.04%
+0.82%
-0.28%
+1.10%
+3.20%Popular Instruments
52145.700
+855.100 (+1.67%)
27758.700
+794.200 (+2.94%)
7524.100
+144.100 (+1.95%)
12797.000
-1.000 (-0.01%)
60395.000
+2253.000 (+3.88%)
6288.200
+147.600 (+2.40%)
87.632
-2.225 (-2.48%)
351.260
+8.890 (+2.60%)
178.650
-7.990 (-4.28%)
4118.790
+53.120 (+1.31%)
FAQs
What is the current price of Arcturus Therapeutics Holdings Inc (ARCT)?
The current price of Arcturus Therapeutics Holdings Inc (ARCT) is 10.35.
What is the symbol of Arcturus Therapeutics Holdings Inc?
The ticker symbol of Arcturus Therapeutics Holdings Inc is ARCT.
What is the 52-week high of Arcturus Therapeutics Holdings Inc?
The 52-week high of Arcturus Therapeutics Holdings Inc is 17.96.
What is the 52-week low of Arcturus Therapeutics Holdings Inc?
The 52-week low of Arcturus Therapeutics Holdings Inc is 5.50.
What is the market capitalization of Arcturus Therapeutics Holdings Inc?
The market capitalization of Arcturus Therapeutics Holdings Inc is 294.15M.
Is Arcturus Therapeutics Holdings Inc (ARCT) currently rated as Buy, Hold, or Sell?
According to analysts, Arcturus Therapeutics Holdings Inc (ARCT) has an overall rating of Buy, with a price target of 24.22.
What is the Earnings Per Share (EPS TTM) of Arcturus Therapeutics Holdings Inc (ARCT)?
The Earnings Per Share (EPS TTM) of Arcturus Therapeutics Holdings Inc (ARCT) is -2.83.